Hospital
Ihc Health Services INC
Ihc Health Services INC was paid $15.31M by Medicaid between Jan 2018 and Sep 2024, across 137 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 78% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES INC
RIVERTON, UT 84065
RIVERTON, UT 84065
33aNPI1154551919assigned 07/15/2009
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.31M
24GClaims189,118
24DCodes billed137
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#7 of 26
Median peer was paid$6.14M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, DENIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,119 | $2.20M | |
| 2019 | 30,220 | $2.39M | |
| 2020 | 36,224 | $2.87M | |
| 2021 | 47,877 | $3.77M | |
| 2022 | 45,650 | $3.90M | |
| 2023 | 2,567 | $154K | |
| 2024incomplete | 461 | $27K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 78% | 27,191 | 14,368 | $11.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.8% | 8,929 | 8,073 | $436K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 11,795 | 9,911 | $427K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 2,252 | 2,109 | $331K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 6,259 | 5,318 | $284K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.3% | 9,458 | 8,421 | $196K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,944 | 1,791 | $105K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,730 | 1,596 | $85K |
| 80050 | General health panel | <1% | 1,140 | 1,062 | $84K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,483 | 1,109 | $84K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 4,318 | 3,815 | $74K |
| 81001 | <1% | 6,862 | 6,070 | $70K |
125 more codes
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,068 | $69K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,219 | $66K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,652 | $63K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,918 | $60K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 747 | $55K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,795 | $50K |
| 85027 | <1% | 1,330 | $46K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,140 | $43K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 336 | $42K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,563 | $42K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,601 | $42K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,651 | $42K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,801 | $39K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,454 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,931 | $30K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,725 | $28K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,137 | $26K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,208 | $25K |
| 87081 | <1% | 1,420 | $23K | |
| 0001A | <1% | 738 | $20K | |
| 0002A | <1% | 704 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 463 | $19K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 672 | $18K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 886 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 10,398 | $17K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 312 | $17K |
| 84702 | <1% | 3,527 | $16K | |
| 82330 | <1% | 853 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,550 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,098 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,056 | $13K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,502 | $13K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,873 | $11K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 59 | $11K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 874 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,066 | $10K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 130 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,248 | $10K |
| 74018 | <1% | 101 | $9K | |
| 86901 | <1% | 360 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,869 | $9K |
| 83690 | <1% | 3,497 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 472 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 191 | $8K |
| 87186 | <1% | 985 | $8K | |
| 87631 | <1% | 124 | $7K | |
| 85651 | <1% | 636 | $6K | |
| 84484 | <1% | 2,088 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 781 | $6K |
| 83605 | <1% | 2,834 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,764 | $5K |
| 96376 | <1% | 729 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 30 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 468 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 161 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 236 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 699 | $3K |
| 76801 | <1% | 144 | $3K | |
| 73630 | <1% | 74 | $3K | |
| 80061 | Lipid panel | <1% | 375 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 46 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 352 | $2K |
| 85610 | <1% | 997 | $2K | |
| 0031A | <1% | 132 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 403 | $2K |
| 73610 | <1% | 50 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 312 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 76 | $1K |
| 91300 | <1% | 114 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 17 | $1K |
| 85379 | <1% | 667 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 235 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 207 | $979.91 |
| 73562 | <1% | 16 | $950.46 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 269 | $911.10 |
| 84703 | <1% | 216 | $908.83 | |
| 84439 | <1% | 509 | $877.72 | |
| 82247 | <1% | 70 | $875.84 | |
| 87088 | <1% | 882 | $821.54 | |
| 86140 | <1% | 1,050 | $735.38 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 34 | $652.48 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 26 | $599.53 |
| 83735 | <1% | 721 | $584.87 | |
| 83880 | <1% | 43 | $546.90 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 22 | $469.75 |
| 87070 | <1% | 91 | $466.77 | |
| 80076 | <1% | 16 | $402.71 | |
| 93971 | <1% | 27 | $329.39 | |
| 82248 | <1% | 67 | $301.52 | |
| 73030 | <1% | 14 | $263.40 | |
| 87449 | <1% | 12 | $214.27 | |
| 87077 | <1% | 45 | $180.75 | |
| 87040 | <1% | 239 | $165.13 | |
| 82657 | <1% | 124 | $142.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 129 | $121.61 |
| 82570 | <1% | 40 | $106.23 | |
| 82728 | <1% | 150 | $90.95 | |
| 85007 | <1% | 107 | $52.80 | |
| 84100 | <1% | 60 | $39.88 | |
| J3490 | Unclassified drugs | <1% | 45 | $10.80 |
| 86850 | <1% | 43 | $2.60 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 704 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| 83540 | 0% | 26 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 12 | $0.00 |
| 86900 | 0% | 32 | $0.00 | |
| 82565 | 0% | 12 | $0.00 | |
| 88302 | 0% | 17 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 76 | $0.00 |
| 82803 | 0% | 118 | $0.00 | |
| 70496 | 0% | 15 | $0.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 195 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 96 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 155 | $0.00 |
| 83615 | 0% | 46 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 41 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 41 | $0.00 |
| 84132 | 0% | 14 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 12 | $0.00 |
| 85730 | 0% | 44 | $0.00 | |
| 90686 | 0% | 26 | $0.00 | |
| 82607 | 0% | 12 | $0.00 | |
| 84478 | 0% | 26 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, DENIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | Murray, UT | $68.77M |
| Ihc Health Services, INC. | St George, UT | $65.78M |
| Ihc Health Services INC | Ogden, UT | $54.08M |
| Ihc Health Services, INC. | Provo, UT | $44.35M |
| Ihc Health Services INC | Logan, UT | $25.34M |
| Ihc Health Services, INC. | Cedar City, UT | $20.40M |
| Ihc Health Services, INC. | Salt Lake City, UT | $19.91M |
| Ihc Health Services, INC. | American Fork, UT | $17.19M |
| Ihc Health Services INC | Sandy, UT | $11.66M |
| Ihc Health Services, INC. | Layton, UT | $11.61M |
| Ihc Health Services, INC. | Burley, ID | $5.14M |
| Ihc Health Services INC | Murray, UT | $4.64M |
| Ihc Health Services INC | St George, UT | $4.35M |
| Ihc Health Services INC | Heber City, UT | $4.31M |
| Ihc Health Services, INC. | Orem, UT | $4.18M |
| Ihc Health Services, INC. | Richfield, UT | $3.87M |
| Ihc Health Services INC | Tremonton, UT | $3.55M |
| Ihc Health Services, INC. | Spanish Fork, UT | $3.49M |
| Ihc Health Services INC | Park City, UT | $2.53M |
| Ihc Health Services, INC. | Mt Pleasant, UT | $2.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.